Journal of the American Academy of Dermatology · 2014
Primary cutaneous perivascular epithelioid cell tumor: a clinicopathological and molecular reappraisal.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Charli-Joseph Yann, Saggini Andrea, Vemula Swapna, Weier Jingly, Mirza Sonia, LeBoit Philip E
Аннотация
BACKGROUND: Perivascular epithelioid cell tumor (PEComa) is a rare neoplasm of uncertain histogenesis with a mixed myomelanocytic immunophenotype, rarely arising in the skin (primary cutaneous PEComa [pcPEComa]).
OBJECTIVE: We analyzed the clinicopathological features of 8 pcPEComas, assayed for DNA copy number changes and for initiating mutations common in melanocytic neoplasms.
METHODS: pcPEComas were evaluated using immunohistochemistry, comparative genomic hybridization, and DNA sequencing.
RESULTS: pcPEComas were erythematous nodules, mostly in the lower extremities of women (5/8), composed of large pale-staining epithelioid cells. The patient's age range was 26 to 67 (mean 46) years. The percentages of tumors staining positively were as follows: micro-ophthalmia-associated transcription factor, NKI/C3, bcl-1, E-cadherin, and cathepsin K (100%); HMB-45, 4E-binding protein 1, and CD68 (88%); smooth muscle actin and muscle-specific actin (40%); S100 (38%); calponin (20%); desmin (13%); and melan-A, SOX10, and keratin (0%). No chromosomal copy number changes or initiating mutations were identified.
LIMITATIONS: Small sample size is a limitation.
CONCLUSIONS: pcPEComas have a different molecular signature than extracutaneous tumors and are unrelated to tuberous sclerosis. However, the common expression of 4E-binding protein 1 points to a role of the mTOR pathway in their pathogenesis. Because pcPEComas are diagnostically challenging, we propose that micro-ophthalmia-associated transcription factor, NKIC3, smooth muscle actin, desmin, bcl-1, cathepsin K, and 4E-binding protein 1 can be used when evaluating a possible pcPEComa.
OBJECTIVE: We analyzed the clinicopathological features of 8 pcPEComas, assayed for DNA copy number changes and for initiating mutations common in melanocytic neoplasms.
METHODS: pcPEComas were evaluated using immunohistochemistry, comparative genomic hybridization, and DNA sequencing.
RESULTS: pcPEComas were erythematous nodules, mostly in the lower extremities of women (5/8), composed of large pale-staining epithelioid cells. The patient's age range was 26 to 67 (mean 46) years. The percentages of tumors staining positively were as follows: micro-ophthalmia-associated transcription factor, NKI/C3, bcl-1, E-cadherin, and cathepsin K (100%); HMB-45, 4E-binding protein 1, and CD68 (88%); smooth muscle actin and muscle-specific actin (40%); S100 (38%); calponin (20%); desmin (13%); and melan-A, SOX10, and keratin (0%). No chromosomal copy number changes or initiating mutations were identified.
LIMITATIONS: Small sample size is a limitation.
CONCLUSIONS: pcPEComas have a different molecular signature than extracutaneous tumors and are unrelated to tuberous sclerosis. However, the common expression of 4E-binding protein 1 points to a role of the mTOR pathway in their pathogenesis. Because pcPEComas are diagnostically challenging, we propose that micro-ophthalmia-associated transcription factor, NKIC3, smooth muscle actin, desmin, bcl-1, cathepsin K, and 4E-binding protein 1 can be used when evaluating a possible pcPEComa.
Предметные рубрики MeSH
Adaptor Proteins, Signal TransducingAdultAgedAntigens, CDAntigens, Differentiation, MyelomonocyticBiopsyCathepsin KCell Cycle ProteinsComparative Genomic HybridizationCyclin D1DNA Copy Number VariationsDesminFemaleHumansImmunoenzyme TechniquesMaleMicrophthalmia-Associated Transcription FactorMiddle AgedPerivascular Epithelioid Cell NeoplasmsPhosphoproteinsSkin NeoplasmsCD68 Molecule